中国肝脏病杂志(电子版)

位置：首页 >> 期刊文章

阿德福韦酯片治疗E抗原阳性的慢性乙型肝炎临床观察

作者：王健

单位：太原市传染病医院太原 030012

分类号：

出版年,卷(期):页码：2010,2(2):18-21

摘要：

目的评价国产阿德福韦酯（ADV）片治疗HBeAg阳性慢性乙型肝炎患者的安全性与效果。方法采用随机对照方法，观察131例HBeAg阳性慢性乙型肝炎患者经口服阿德福韦酯片10 mg/d，和口服苦参素胶囊0.6 g/d，48周治疗期间和治疗后，血清HBA DNA阴转率、ALT复常率、HBeAg阴转率，抗-HBe阳转率及不良反应。结果实验组血清HBV DNA阴转率、ALT复常率、HBeAg阴转率、抗-HBe阳转率均高于对照组，分别为53.2%/7.8%、36.0%/8.7%、13.6%/3.1%、6.2%/0（χ2值分别为56.32，23.18，P ＜ 0.01；四格表确切概率法检验，P ＜ 0.01）。实验组和对照组则分别为78.0%/9.6%、56.8%/28.7%、32.1%/11.7%、18.7%/6.3%（χ2值分别为76.78、21.72、20.61、21.32，P ＜ 0.01）。结论国产阿德福韦酯片治疗HBeAg阳性慢性乙型肝炎的安全性及有效性均明显优于苦参素对照组。

Objective To evaluate the safety and effect of adefovir dipivoxil (ADV) in HBeAg-positive patients with chronic hepatitis B. Methods All 131 patients were divided into two groups randomly. Two groups were treated with ADV (10 mg/d) and marine capsules (0.6 g/d), respectively. The rate of HBV DNA negative, the normalization rates of ALT, HBeAg negative rate, anti-HBe seroconversion and adverse effect were evaluated, respectively. Results The rate of HBV DNA negative, the normalization rates of ALT, HBeAg negative rate and anti-HBe seroconversion of adefovir dipivoxil were all signiicantly higher than those of control group (53.2%/7.8%, 36.0%/8.7%, 13.6%/3.1%, 6.2%/0, respectively, χ2 = 56.32, 23.18, P ＜ 0.01). The rate of experimental group and control group respectively are 78.0%/9.6%, 56.8%/28.7%, 32.1%/11.7%, 18.7%/6.3%（χ2 are respectively 76.78, 21.72, 20.61, 21.32, P ＜ 0.01). Conclusions The safety and eficacy of domestic adefovir dipivoxil is superior to marine capules in HBeAg-positive patients.

基金项目：

作者简介：

参考文献：

服务与反馈：

【文章下载】【加入收藏】